# miR-142-3p as Potential Biomarker of Synaptopathy in MS

> **NCT03999788** · NA · UNKNOWN · sponsor: **Neuromed IRCCS** · enrollment: 1000 (estimated)

## Conditions studied

- Multiple Sclerosis
- Spasticity

## Interventions

- **PROCEDURE:** lumbar puncture and blood withdrawal
- **PROCEDURE:** Intermittent theta burst stimulation (iTBS) therapeutic protocol for spasticity

## Key facts

- **NCT ID:** NCT03999788
- **Lead sponsor:** Neuromed IRCCS
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-10
- **Primary completion:** 2024-12-28
- **Final completion:** 2025-12-28
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03999788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03999788, "miR-142-3p as Potential Biomarker of Synaptopathy in MS". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03999788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*